JAMA Network Open
Original Investigation
Oncology
March 19, 2020
Alexander F. Bagley, MD, PhD; Mitchell S. Anscher, MD; Seungtaek Choi, MD; Steven J. Frank, MD; Karen E. Hoffman, MD; Deborah A. Kuban, MD; Sean E. McGuire, MD, PhD; Quynh-Nhu Nguyen, MD; Brian Chapin, MD; Ana Aparicio, MD; Todd A. Pezzi, MD, MBA; Grace L. Smith, MD, PhD, MPH; Benjamin D. Smith, MD; Kenneth Hess, PhD; Chad Tang, MD
open access
JAMA Netw Open. 2020; 3(3):e201255. doi: 10.1001/jamanetworkopen.2020.1255
This cohort study identifies sociodemographic and health-related factors associated with receipt of nondefinitive therapy among patients aged 70 years and younger with high-risk prostate cancer.
JAMA Oncology
Original Investigation
November 1, 2019
Dawei Chen, MD; Hari Menon, BS; Vivek Verma, MD; Steven N. Seyedin, MD; Jaffer A. Ajani, MD; Wayne L. Hofstetter, MD; Quynh-Nhu Nguyen, MD; Joe Y. Chang, MD, PhD; Daniel R. Gomez, MD; Arya Amini, MD; Stephen G. Swisher, MD; Mariela A. Blum, MD; Ahmed I. Younes, MD; Hampartsoum B. Barsoumian, PhD; Jeremy J. Erasmus, MD; Jeffrey H. Lee, MD; Manoop S. Bhutani, MD; Kenneth R. Hess, PhD; Bruce D. Minsky, MD; James W. Welsh, MD
free access
JAMA Oncol. 2019; 5(11):1597-1604. doi: 10.1001/jamaoncol.2019.2809
This phase 1/2 single-arm trial examined toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer.
JAMA Oncology
Original Investigation
June 1, 2019
Quynh-Nhu Nguyen, MD; Stephen G. Chun, MD; Edward Chow, MBBS, PhD; Ritsuko Komaki, MD; Zhongxing Liao, MD; Rensi Zacharia, MD; Bill K. Szeto, BA; James W. Welsh, MD; Stephen M. Hahn, MD; C. David Fuller, MD; Bryan S. Moon, MD; Justin E. Bird, MD; Robert Satcher, MD; Patrick P. Lin, MD; Melenda Jeter, MD; Michael S. O’Reilly, MD; Valerae O. Lewis, MD
free access
has multimedia
JAMA Oncol. 2019; 5(6):872-878. doi: 10.1001/jamaoncol.2019.0192
This randomized phase 2 noninferiority trial assessed the efficacy of high-dose, single-fraction stereotactic radiation therapy vs standard multifraction radiation therapy for pain relief in patients with mostly nonspine bone metastases.
JAMA Network Open
Original Investigation
Oncology
August 24, 2018
Eric D. Brooks, MD; Bing Sun, MD; Lei Feng, MS; Vivek Verma, MD; Lina Zhao, MD; Daniel R. Gomez, MD; Zhongxing Liao, MD; Melenda Jeter, MD; Michael O’Reilly, MD; James W. Welsh, MD; Quynh-Nhu Nguyen, MD; Jeremy J. Erasmus, MD; George Eapen, MD; Kamran Ahrar, MD; Mara B. Antonoff, MD; Stephen M. Hahn, MD; John V. Heymach, MD; David C. Rice, MD; Joe Y. Chang, MD
open access
online only
JAMA Netw Open. 2018; 1(4):e181390. doi: 10.1001/jamanetworkopen.2018.1390
This cohort study examines long-term outcomes for patients with isolated local recurrence or isolated regional recurrence after stereotactic ablative radiotherapy for early-stage non–small cell lung cancer with the aim of informing treatment decision making.